Abstract 809P
Background
Gynecological cancer may have severe implications in women, as these diagnoses are likely to have negative consequences on mental health and socioeconomic status. We used the Swedish national population and healthcare registries to assess the association between diagnosis of endometrial or cervical cancer and risk for mental disorders, as well as for socioeconomic consequences.
Methods
We performed a population-based nested case-control study based on more than 5 million women in Sweden, identifying 6,060 cases of cervical cancer and 17,932 cases of endometrial cancer diagnosed during 2006-2018. Each cancer case was matched with five healthy controls randomly selected from the population born in the same year. Data on comprehensive set of mental disorders, loss of employment, early retirement or need for sickness benefit, family receipt of financial assistance, decrease of individual income and family income before versus after cancer diagnosis were retrieved from population registries. Conditional logistic regression and stratified Cox regression models with confounder adjustment were conducted to estimate odds ratios (OR) and 95% confidence intervals (CI).
Results
Mental disorders were prevalent to a moderate degree before diagnosis among cervical cancer patients, but less prevalent in endometrial cancer patients. After cancer diagnosis, incident (i.e. new) mental disorders started emerging within the first 2-5 years and then persisted. The risk was higher following cervical cancer (OR=3.7, 95% CI=3.5-4.1) as compared to endometrial cancer (OR=2.1, 95% CI=2.0-2.2). Before cancer diagnosis, economic status was comparable between cancer patients and control women. Financial assistance and income decrease rose early after diagnosis, with 1.2-2.1 times increased risk among cancer patients. Unemployment, early retirement and need for sickness benefit doubled from two years after cancer diagnosis and onwards. Impact was more pronounced among cervical cancer patients.
Conclusions
Women with cervical cancer and endometrial cancer are affected mentally and financially after the cancer diagnosis. The impact is more pronounced among cervical cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
MSD Sweden.
Disclosure
J. Wang, K. Sundström: Financial Interests, Institutional, Research Funding: MSD. A.L. Feldman: Financial Interests, Institutional, Other: Has been part of research collaborations within partnership programs between Karolinska Institutet and respectively MSD Sweden/Merck and Janssen Pharmaceutica NV. G. Bencina, M. Andersson, S. Salomonsson: Financial Interests, Personal, Full or part-time Employment: MSD. All other authors have declared no conflicts of interest.
Resources from the same session
789P - Real-world (RW) duration of treatment in first-line maintenance (1Lm) niraparib monotherapy in epithelial ovarian cancer (EOC): CHAR1ZMA study
Presenter: Floor Backes
Session: Poster session 11
790P - Uniform prospective molecular analysis of endometrial carcinoma: Feasibility, outcomes, and effect on management
Presenter: Bradley Corr
Session: Poster session 11
791P - Development and validation of nomograms to predict survival in patients with high-grade serous ovarian cancer
Presenter: Xiaolian Peng
Session: Poster session 11
792P - Prognostic role of the modeled CA-125 KELIM in early FIGO stage I and II ovarian cancers (OC): A GCIG individual-patient data meta-analysis
Presenter: Pauline Corbaux
Session: Poster session 11
793P - Strong relationships between the CA-125 KELIM score and the tumor biological effects after neo-adjuvant chemotherapy in advanced ovarian cancer patients: CHIVA trial (GINECO)
Presenter: Ana Maria Catana
Session: Poster session 11
794P - Efficacy of gemcitabine (gem) based therapy in ovarian clear cell carcinoma (OCCC)
Presenter: Jerold Loh
Session: Poster session 11
795P - Tolerability and effectiveness of niraparib in long-term responders with platinum-sensitive recurrent ovarian cancer (GEICO-88R study)
Presenter: Juan Cueva Banuelos
Session: Poster session 11
796P - Initial management and long-term outcome of advanced low-grade serous ovarian cancer (LGSOC) exploring role of surgery and maintenance therapy in the French multicentre ESME database
Presenter: Thomas Papazyan
Session: Poster session 11
797P - Impact of consolidation cycles in predicting recurrence in patients treated with EMA-CO for high-risk gestational trophoblastic neoplasia
Presenter: Antoine DELEUZE
Session: Poster session 11
798P - Survival analysis of non-metastatic gestational choriocarcinoma (NMGCC) patients treated with chemotherapy
Presenter: Sakhr Alshwayyat
Session: Poster session 11